OverviewSuggest Edit

Spark Therapeutics is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases.

TypePublic
Founded2013
HQPhiladelphia, US
Websitesparktx.com
Employee Ratings3

Latest Updates

Employees (est.) (Feb 2019)368(+17%)
Job Openings39
Revenue (FY, 2018)$64.7 M(+437%)
Share Price (Nov 2019)$111.4

Key People/Management at Spark Therapeutics

Jeffrey D. Marrazzo

Jeffrey D. Marrazzo

Co-Founder, President and CEO
J. Fraser Wright

J. Fraser Wright

Scientific Co-Founder and CTO
Katherine A. High

Katherine A. High

Scientific Co-Founder
Show more

Spark Therapeutics Office Locations

Spark Therapeutics has an office in Philadelphia
Philadelphia, US (HQ)
3737 Market St
Show all (1)

Spark Therapeutics Financials and Metrics

Spark Therapeutics Revenue

Spark Therapeutics's revenue was reported to be $64.73 m in FY, 2018
USD

Revenue (Q1, 2019)

20.8m

Gross profit (Q1, 2019)

20.0m

Gross profit margin (Q1, 2019), %

96.4%

Net income (Q1, 2019)

(54.4m)

EBIT (Q1, 2019)

(56.8m)

Market capitalization (11-Nov-2019)

4.2b

Closing stock price (11-Nov-2019)

111.4

Cash (31-Mar-2019)

76.3m

EV

4.2b
Spark Therapeutics's current market capitalization is $4.2 b.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

633.9k22.1m20.2m12.1m64.7m

Revenue growth, %

3380%(9%)

Cost of goods sold

1.0m

Gross profit

63.7m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Revenue

2.3m1.3m1.3m1.3m1.3m1.3m1.3m1.5m1.9m15.7m25.2m10.7m20.8m

Cost of goods sold

121.0k269.0k318.0k745.0k

Gross profit

15.6m24.9m10.4m20.0m

Gross profit Margin, %

99%99%97%96%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

74.6m293.5m58.9m96.7m95.2m

Accounts Receivable

244.4k16.9m16.8m

Inventories

25.6m

Current Assets

77.4m311.6m314.6m533.2m567.1m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Cash

234.4m223.0m212.2m275.0m225.0m90.6m27.5m36.8m146.4m127.7m201.1m161.6m76.3m

Accounts Receivable

669.4k933.1k1.3m812.8k1.2m1.0m5.9m5.0m

Inventories

5.6m12.7m20.7m30.1m

Current Assets

235.9m225.1m214.3m277.8m335.3m309.2m263.4m226.3m489.1m621.0m691.6m635.2m513.4m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(24.3m)(47.1m)(123.7m)(253.5m)(78.8m)

Depreciation and Amortization

169.8k1.7m3.6m4.9m6.9m

Inventories

(25.6m)

Accounts Payable

2.3m9.1m10.0m13.0m8.7m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019

Net Income

(9.7m)(24.1m)(41.0m)(25.6m)(54.3m)(86.8m)(52.3m)(126.6m)(191.7m)(46.4m)33.8m(13.6m)(54.4m)

Depreciation and Amortization

370.6k797.2k1.2m744.1k1.7m2.6m1.0m2.2m3.5m1.5m3.1m4.8m2.4m

Inventories

(5.6m)(12.7m)(20.7m)(4.5m)

Accounts Payable

870.4k3.2m7.7m(1.1m)(2.0m)4.2m(2.7m)4.8m839.4k(8.4m)(8.0m)(877.0k)(3.8m)
USDY, 2019

EV/EBIT

-73.5 x

EV/CFO

-130.2 x

Revenue/Employee

56.4k

Financial Leverage

1.7 x
Show all financial metrics

Spark Therapeutics Operating Metrics

FY, 2016

Patents and Patent Applications

297
Show all operating metrics

Spark Therapeutics Online and Social Media Presence

Embed Graph

Spark Therapeutics News and Updates

Spark Therapeutics Wins Prix Galien USA Award for LUXTURNA® (voretigene neparvovec-rzyl) as Best Biotechnology Product

PHILADELPHIA, Oct. 25, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today announced that the Galien Foundation has awarded the prestigious 2019 Prix Galien USA Award for…

Dow Jones Newswires: U.K.’s competition watchdog opens probe into Roche takeover of Spark Therapeutics

The regulator said it is looking into whether the deal will result in a substantial lessening of competition, and has set Dec. 16 as its deadline to decide whether it will continue the investigation.

Spark Therapeutics Announces Change of Location for Annual Meeting of Stockholders

PHILADELPHIA, Aug. 27, 2019 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully-integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, announced today the location of its 2019 Annual Meeting of Stockholders, to be held on Sept. 5, 2019,…

Roche and Spark Therapeutics, Inc. announce extension of tender offer for shares of Spark Therapeutics, Inc.

Pursuant to the Agreement and Plan of Merger, dated as of February 22, 2019, by and among Roche Holdings, Inc., 022019 Merger Subsidiary, Inc., and Spark (as amended, the “Merger Agreement”), the Offer, which was previously scheduled to expire at 5:00 p.m., New York City time, on Wednesday, July 31,…

Roche and Spark Therapeutics, Inc. receive Request for Additional Information from FTC under Hart-Scott-Rodino Act and announce extension of tender offer for shares of Spark Therapeutics, Inc.

Basel, 10 June 2019 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Spark Therapeutics, Inc. (NASDAQ: ONCE) (“Spark”) today announced that they have each received a request for additional information and documentary material (the “Second Request”) from the U.S. Federal Trade Commission (the “FTC”) in conne…

Spark Therapeutics Announces Sponsorship of Believe Limited’s First-Ever Science Fair for the Hemophilia Community at 2019 National Hemophilia Foundation’s Bleeding Disorders Conference

The Science Fair™ aims to engage and educate patients, families and caregivers affected by bleeding The Science Fair™ aims to engage and educate patients, families and caregivers affected by bleeding
Show more

Spark Therapeutics Blogs

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights

Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Results and Recent Business Highlights Content Import Tue, 10/30/2018 - 07:32 Spark Therapeutics to Host Conference Call on Tuesday, Nov. 6 at 8:30 a.m. ET to Discuss Third Quarter Resu…

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases Content Import Thu, 10/25/2018 - 07:34 Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for…

Spark Therapeutics Announces New Preclinical Data for Pompe Disease Gene Therapy Candidate

Data from IND-enabling studies in three species support moving SPK-3006 into the clinic in 2019 PHILADELPHIA , Oct. 08, 2018 (GLOBE NEWSWIRE) -- Spark Therapeutics (NASDAQ:ONCE), a fully integrated, commercial gene therapy company dedicated to challenging the inevitability of genetic disease, today

Spark Therapeutics Frequently Asked Questions

  • When was Spark Therapeutics founded?

    Spark Therapeutics was founded in 2013.

  • Who are Spark Therapeutics key executives?

    Spark Therapeutics's key executives are Jeffrey D. Marrazzo, J. Fraser Wright and Katherine A. High.

  • How many employees does Spark Therapeutics have?

    Spark Therapeutics has 368 employees.

  • What is Spark Therapeutics revenue?

    Latest Spark Therapeutics annual revenue is $64.7 m.

  • What is Spark Therapeutics revenue per employee?

    Latest Spark Therapeutics revenue per employee is $175.9 k.

  • Who are Spark Therapeutics competitors?

    Competitors of Spark Therapeutics include Arrogene, Mesoblast and ImmusanT.

  • Where is Spark Therapeutics headquarters?

    Spark Therapeutics headquarters is located at 3737 Market St, Philadelphia.

  • Where are Spark Therapeutics offices?

    Spark Therapeutics has an office in Philadelphia.

  • How many offices does Spark Therapeutics have?

    Spark Therapeutics has 1 office.